Division of Pulmonary, Allergy, and Critical Care, Department of Medicine.
Center for Clinical Epidemiology and Biostatistics, and.
Ann Am Thorac Soc. 2021 Apr;18(4):598-605. doi: 10.1513/AnnalsATS.202006-590OC.
Prior studies investigating associations of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) seropositivity with risk for rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) have mostly used cross-sectional or case-control designs. To determine whether combined autoantibody seropositivity and higher individual autoantibody concentrations were associated with increased risk for RA-ILD in a prospective RA cohort. Within the Veterans Affairs Rheumatoid Arthritis prospective registry, we performed a cross-sectional study of prevalent ILD and a retrospective cohort study of incident ILD (diagnosed after at least 12 mo of longitudinal follow-up). We used logistic and Cox regression methods to determine whether combined RF/ACPA seropositivity and higher autoantibody concentrations were independently associated with greater risk for prevalent and incident ILD, respectively. Among 2,328 participants (median age 64 yr, 89.3% male), 100 (4.3%) subjects had prevalent ILD at enrollment. During 14,281 patient-years of follow-up, 83 (3.7%) of the remaining 2,228 were subsequently diagnosed with incident ILD (5.8 cases per 1,000 person-years). Patients with combined RF/ACPA seropositivity had a higher probability of prevalent ILD compared with seronegative subjects (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.24-6.78). RF titers demonstrated a monotonic association with prevalent ILD (OR, 2.69; 95% CI, 1.11-6.51 for low-positive [15-45 IU/ml] titers; OR, 3.40; 95% CI, 1.61-7.18 for high-positive [>45 IU/ml] titers; for trend 0.01). Patients with high-positive (>15 U/ml) ACPA titers were also at higher risk for prevalent ILD (OR, 1.91; 95% CI, 1.04-3.49) compared with ACPA-negative subjects. Combined RF/ACPA seropositivity was not associated with increased risk for incident ILD, nor were high- or low-positive RF or ACPA titers. In a piecewise linear spline model, however, RF titers greater than 90 IU/ml independently correlated with increased risk for incident ILD (hazard ratio, 1.68, 95% CI, 1.02-2.77). Combined RF/ACPA seropositivity and individual autoantibody concentrations were strongly associated with prevalent but not incident RA-ILD. Only patients with RF concentrations >90 IU/ml were observed to be at higher risk of incident RA-ILD.
先前的研究调查了类风湿因子 (RF) 和抗瓜氨酸蛋白抗体 (ACPA) 血清阳性与类风湿关节炎 (RA) 相关间质性肺病 (ILD) 风险之间的关联,这些研究大多使用了横断面或病例对照设计。为了确定在一个前瞻性 RA 队列中,联合自身抗体血清阳性和更高的个体自身抗体浓度是否与 RA-ILD 的风险增加相关。在退伍军人事务部类风湿关节炎前瞻性登记处,我们对现患 ILD 进行了横断面研究,并对新发 ILD 进行了回顾性队列研究(在至少 12 个月的纵向随访后诊断)。我们使用逻辑和 Cox 回归方法来确定联合 RF/ACPA 血清阳性和更高的自身抗体浓度是否分别与现患和新发 ILD 的风险增加独立相关。在 2328 名参与者(中位年龄 64 岁,89.3%为男性)中,100 名(4.3%)受试者在入组时患有现患 ILD。在 14281 患者年的随访中,2228 名剩余受试者中有 83 名(3.7%)随后被诊断为新发 ILD(每 1000 人年 5.8 例)。与血清阴性患者相比,联合 RF/ACPA 血清阳性患者现患 ILD 的可能性更高(比值比 [OR],2.90;95%置信区间 [CI],1.24-6.78)。RF 滴度与现患 ILD 呈单调关联(低阳性 [15-45IU/ml] 滴度的 OR,2.69;95%CI,1.11-6.51;高阳性 [>45IU/ml] 滴度的 OR,3.40;95%CI,1.61-7.18;趋势检验 P=0.01)。高阳性 (>15U/ml) ACPA 滴度的患者也有更高的现患 ILD 风险(OR,1.91;95%CI,1.04-3.49),与 ACPA 阴性患者相比。联合 RF/ACPA 血清阳性与新发 ILD 风险增加无关,高或低阳性 RF 或 ACPA 滴度也无关。然而,在分段线性样条模型中,RF 滴度大于 90IU/ml 与新发 ILD 的风险增加独立相关(危险比,1.68,95%CI,1.02-2.77)。联合 RF/ACPA 血清阳性和个体自身抗体浓度与现患 RA-ILD 强烈相关,但与新发 RA-ILD 无关。只有观察到 RF 浓度>90IU/ml 的患者发生新发 RA-ILD 的风险更高。